LEXINGTON, Mass., Jan. 13, 2022 /PRNewswire/ -- iSpecimen
Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online
marketplace for human biospecimens, today announced the
expansion of its supplier capabilities with the addition of a
reference lab in New York to
support commercial and government customers focused on COVID-19
research, including analyzing the Omicron and Delta variants. The
reference lab, a recent addition to the iSpecimen supplier network,
has the capacity to sequence hundreds of COVID-19 positive swabs
per week, providing data that is crucial in the fight against the
virus. This lab is sequencing the most recent swabs to identify new
variants of COVID-19 as the virus continues to progress
globally.
"The sequencing of nasal swabs is necessary to determine which
variant a patient has tested positive for and provides
variant-positive specimens for research," said iSpecimen Founder
and CEO, Christopher Ianelli, MD,
Ph.D. "Through our relationship with this reference lab, we are
able to quickly and efficiently support both commercial and
government researchers working day and night to battle
COVID-19."
For researchers looking to validate their own variant
identification assays, iSpecimen can obtain sequenced and
unsequenced COVID-19 positive and negative swabs in a variety of
media types. To learn more about COVID-19 specimens at iSpecimen,
please visit iSpecimen's website
at https://pages.ispecimen.com/COVID-19-Samples.html.
iSpecimen has been working diligently with the research
community to understand COVID-19. In early 2020, iSpecimen
began sending serum samples to the U.S. Centers for Disease
Control and Prevention ("CDC") to help researchers
monitor antibody development for possible guidance on immunity.
iSpecimen has provided the CDC with 600 SARS-CoV-2-positive serum
samples and 100 negative serum samples. In addition, iSpecimen has
provided other federal agencies and private companies custom
COVID-19 collections, which are often complex and complement the
more immediate availability of remnant or banked samples. Overall,
iSpecimen has delivered more than 15,000 specimens for more than
200 COVID-related projects since the start of the
pandemic.
About iSpecimen
iSpecimen offers an online marketplace
for human biospecimens, connecting life scientists in commercial
and non-profit organizations with healthcare providers that have
access to patients and specimens needed for medical discovery.
Proprietary, cloud-based technology enables scientists to
intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements. Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss / Scott Eckstein
iSpecimen@kcsa.com
Media Contact
Kaitlynn
Cooney
For iSpecimen
kcooney@brodeur.com
617.587.2811
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ispecimen-expands-support-of-covid-19-research-with-availability-of-sequenced-specimens-to-detect-variants-301460081.html
SOURCE iSpecimen Inc.